PE20060075A1 - Composiciones farmaceuticas de alisciren - Google Patents

Composiciones farmaceuticas de alisciren

Info

Publication number
PE20060075A1
PE20060075A1 PE2005000288A PE2005000288A PE20060075A1 PE 20060075 A1 PE20060075 A1 PE 20060075A1 PE 2005000288 A PE2005000288 A PE 2005000288A PE 2005000288 A PE2005000288 A PE 2005000288A PE 20060075 A1 PE20060075 A1 PE 20060075A1
Authority
PE
Peru
Prior art keywords
alisciren
tablet
resulting
active ingredient
granulator
Prior art date
Application number
PE2005000288A
Other languages
English (en)
Inventor
Petra Gisela Rigassi-Dietrich
Martin Schmid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34994415&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060075(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060075A1 publication Critical patent/PE20060075A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA FORMULACION QUE COMPRENDE: A) UN INHIBIDOR DE RENINA TAL COMO ALISCIREN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, DONDE EL INGREDIENTE ACTIVO ESTA PRESENTE EN UNA CANTIDAD QUE VARIA ENTRE 46-60% EN PESO; B) UN LLENADOR TAL COMO CELULOSA MICROCRISTALINA; C) AGENTE DE DESINTEGRACION, LUBRICANTE, AGENTE DE DESLIZ, AGLUTINANTE. UN PROCEDIMIENTO DE PREPARACION COMPRENDE: 1) MEZCLAR EL INGREDIENTE ACTIVO Y ADITIVOS Y GRANULAR DICHOS COMPONENTES CON UN LIQUIDO GRANULACION; 2) SECAR UN GRANULADOR RESULTANTE; 3) MEZCLAR EL GRANULADOR SECO CON EXCIPIENTES DE FASE EXTERNA; 4) COMPRIMIR UNA MEZCLA RESULTANTE PARA FORMAR UNA DOSIS ORAL SOLIDA COMO UNA TABLETA DE NUCLEO; 5) OPCIONALMENTE RECUBRIR UNA TABLETA DE NUCLEO RESULTANTE PARA DAR UNA TABLETA CUBIERTA CON PELICULA. DICHA FORMULACION SUPERA LOS PROBLEMAS RELACIONADOS CON LAS PROPIEDADES DEL ALISCIREN. SON UTILES EN EL TRATAMIENTO DE HIPERTENSION, FALLA CARDIACA CONGESTIVA, ANGINA, INFARTO DE PECHO, DOLOR DE CABEZA, ENTRE OTROS
PE2005000288A 2004-03-17 2005-03-15 Composiciones farmaceuticas de alisciren PE20060075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55387804P 2004-03-17 2004-03-17

Publications (1)

Publication Number Publication Date
PE20060075A1 true PE20060075A1 (es) 2006-03-20

Family

ID=34994415

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2005000288A PE20060075A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de alisciren
PE2014001265A PE20142101A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren
PE2010000272A PE20110121A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2014001265A PE20142101A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren
PE2010000272A PE20110121A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren

Country Status (24)

Country Link
US (3) US8617595B2 (es)
EP (2) EP1729736A2 (es)
JP (2) JP2007529456A (es)
KR (2) KR101274855B1 (es)
CN (2) CN1997354B (es)
AR (1) AR048431A1 (es)
AU (2) AU2005224010B2 (es)
BR (1) BRPI0508833A (es)
CA (1) CA2554633C (es)
EC (1) ECSP066807A (es)
ES (1) ES2747941T3 (es)
IL (1) IL177424A0 (es)
MA (1) MA28490B1 (es)
MX (1) MX347617B (es)
MY (2) MY144477A (es)
NO (1) NO343217B1 (es)
NZ (1) NZ548823A (es)
PE (3) PE20060075A1 (es)
RU (3) RU2384328C2 (es)
SG (1) SG153830A1 (es)
TN (1) TNSN06294A1 (es)
TW (1) TWI406656B (es)
WO (1) WO2005089729A2 (es)
ZA (1) ZA200606220B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340484T3 (es) * 2002-11-05 2010-06-04 Glaxo Group Limited Agentes antibacterianos.
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US20090062395A1 (en) * 2006-04-03 2009-03-05 Andrew Satlin Renin inhibitors for the treatment of hypertension
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
NZ577320A (en) * 2006-11-07 2012-01-12 Novartis Ag CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide
CN101528672A (zh) * 2006-11-09 2009-09-09 诺瓦提斯公司 阿利吉仑乳清酸盐
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
ES2364538T3 (es) * 2007-09-28 2011-09-06 Novartis Ag Combinación farmacéutica de alisquireno y valsartán.
PE20091203A1 (es) 2007-09-28 2009-09-11 Novartis Ag Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo
CN101808631A (zh) * 2007-09-28 2010-08-18 诺瓦提斯公司 阿利吉仑和缬沙坦的盖仑制剂
EP2220031A1 (en) 2007-11-13 2010-08-25 Teva Pharmaceutical Industries Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
WO2009149344A2 (en) * 2008-06-06 2009-12-10 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
US9026212B2 (en) 2008-09-23 2015-05-05 Incube Labs, Llc Energy harvesting mechanism for medical devices
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
PT2391345E (pt) 2009-01-28 2014-12-03 Novartis Ag Formulações galénicas compreendendo aliscireno
WO2010089105A2 (en) 2009-02-05 2010-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Moisture-activated granulation process
EP2340820A1 (en) 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2216020A1 (en) 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2408433A1 (en) 2009-03-20 2012-01-25 Novartis AG Pharmaceutical composition comprising aliskiren
WO2010107971A1 (en) 2009-03-20 2010-09-23 Novartis Ag Galenical formulations of a fixed dose combination of valsartan and aliskiren
JP2010280601A (ja) * 2009-06-04 2010-12-16 Suntory Holdings Ltd キシロオリゴ糖高含有錠剤
US20120220663A1 (en) 2009-09-03 2012-08-30 Teva Pharmaceuticals Usa, Inc. Solid forms of aliskiren hemifumarate and processes for preparation thereof
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
CN103099793B (zh) * 2013-02-06 2015-07-15 中国人民解放军第二军医大学 片剂及其制备方法
CN103536576B (zh) * 2013-10-15 2015-07-01 海南卫康制药(潜山)有限公司 阿利吉仑组合物胶囊
RU2545833C1 (ru) * 2013-12-03 2015-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России) Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039922A (en) * 1959-08-17 1962-06-19 Carter Prod Inc Method of administering tablets having decongestant and anti-histaminic activity
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
EP1312379A4 (en) 2000-08-25 2004-08-25 Takeda Chemical Industries Ltd FIBRINOGENIC REDUCTION AGENTS
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
JP2003015880A (ja) * 2001-06-29 2003-01-17 Toshiba Corp 携帯情報端末およびアドインプログラム起動方法
EP1448190A2 (en) * 2001-10-18 2004-08-25 Novartis AG Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20030114389A1 (en) 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
CN1655819A (zh) * 2002-05-17 2005-08-17 诺瓦提斯公司 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings

Also Published As

Publication number Publication date
MA28490B1 (fr) 2007-03-01
MY144477A (en) 2011-09-30
MY148773A (en) 2013-05-31
AU2009202069B2 (en) 2012-02-16
ZA200606220B (en) 2008-04-30
CN103462913A (zh) 2013-12-25
KR101353736B1 (ko) 2014-01-22
AU2009202069A1 (en) 2009-06-18
WO2005089729A3 (en) 2006-10-12
US7683054B2 (en) 2010-03-23
RU2438661C2 (ru) 2012-01-10
AR048431A1 (es) 2006-04-26
RU2480210C1 (ru) 2013-04-27
CA2554633C (en) 2014-07-08
IL177424A0 (en) 2008-03-20
RU2009138446A (ru) 2011-04-27
KR101274855B1 (ko) 2013-06-13
TWI406656B (zh) 2013-09-01
US8007824B2 (en) 2011-08-30
JP2007529456A (ja) 2007-10-25
RU2011135405A (ru) 2013-03-10
AU2005224010A1 (en) 2005-09-29
RU2384328C2 (ru) 2010-03-20
RU2006136090A (ru) 2008-04-27
WO2005089729A2 (en) 2005-09-29
PE20110121A1 (es) 2011-02-28
ES2747941T3 (es) 2020-03-12
CA2554633A1 (en) 2006-09-29
US20050272790A1 (en) 2005-12-08
US20060018960A1 (en) 2006-01-26
NZ548823A (en) 2011-02-25
EP2283826A2 (en) 2011-02-16
JP2012211152A (ja) 2012-11-01
CN1997354B (zh) 2013-09-11
EP1729736A2 (en) 2006-12-13
EP2283826A3 (en) 2013-08-07
ECSP066807A (es) 2006-11-16
MX347617B (es) 2017-05-04
US20070197655A1 (en) 2007-08-23
AU2005224010B2 (en) 2009-02-26
JP5925607B2 (ja) 2016-05-25
KR20070006776A (ko) 2007-01-11
EP2283826B1 (en) 2019-09-04
NO343217B1 (no) 2018-12-03
US8617595B2 (en) 2013-12-31
TNSN06294A1 (en) 2007-12-03
NO20064670L (no) 2006-10-16
KR20130028803A (ko) 2013-03-19
CN1997354A (zh) 2007-07-11
PE20142101A1 (es) 2014-12-27
TW200534843A (en) 2005-11-01
BRPI0508833A (pt) 2007-08-14
SG153830A1 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
PE20060075A1 (es) Composiciones farmaceuticas de alisciren
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
AR049000A1 (es) Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida
AR054382A1 (es) Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CA2716874A1 (en) A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
DOP2010000114A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
NI201100154A (es) Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis
GT201300144A (es) Composiciones farmaceuticas
RU2014129508A (ru) Новая комбинация
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
CO2022019131A2 (es) Inhibidores de la quinasa nek7
PE20120422A1 (es) Formulaciones orales solidas de (r)-2-amino-7-[4-fluoro-2-(6-metoxi-piridin-2-il)-fenil]-4-metil-7,8-dihidro-6h-pirido-[4,3-d]-pirimidin-5-ona
BR0214497A (pt) Composição farmacêutica que compreende um agonista do receptor 5ht1
AR045719A1 (es) Formulacion farmaceutica que comprende levotiroxina sodica, celulosa microcristalina y almidon pregelatinizado; uso de la misma para la fabricacion de un medicamento y proceso para preparar dicha formulacion
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
RS54420B1 (en) FORMULATION CONTAINING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE INGREDIENT
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)

Legal Events

Date Code Title Description
FC Refusal